Application of a Novel Combination of Plasma Replacement Solution in Treatment of Hyperviscosity Syndrome

许多荣,陈惠珍,邹外一,陈运贤,原耀光,李娟,杨茂华,黄珊

2009-01-01

Abstract:Objective To investigate the clinical effect and safety of a novel combination of replacement fluid in plasma exchange(PE) in treating hyperviscosity syndrome.Methods One hundred and nine times of PE were performed on 67 patients with hyperviscosity syndrome including 55 cases of multiple myeloma(MM) and 12 cases of Waldenstrom's macroglobulinemia(WM) using CS 3000 plus and COM.TEC blood cell separator.0.9% normal saline solution 500ml,dextran-40 500ml,6% hydroxyethyl starch 500ml and 5% human albumin in saline 500ml were chosen as replacement fluid and supplied each patient with the same type of fresh frozen plasma(FFP) 400ml ～ 600ml after PE.One to four times of PE were performed in one course of treatment for each patient with an interval of about 2 to 7 days.The main adverse effects were investigated during the course of PE.The degree of decrease of IgM or IgG in peripheral blood of each patient and clinical symptoms such as headaches,chest distress,blurred vision,hemorrhagic tendency and Raynaud's symptoms were observed after a course of PE.Results The total incidence of the main adverse reactions during PE were 7.3% and the incidence of citrate intoxation,hypovlemia and allergic response were 4.6%,1.8% and 0.9%,respectively.The average level of IgG in MM patients dropped from 81.9g/L to 38.5g/L(P0.05) and IgM in WM patients dropped from 41.2g/L to 23.4g/L(P 0.05) after one course of treatment.The incidence of clinical symptoms about headaches,chest distress,blurred vision,hemorrhagic tendency and Raynaud's symptoms also dropped dramatically comparing to pre-treatment(P0.05).Conclusion This novel combination of replacement fluid in plasma exchange is economic,safe,and effective and can significantly reduce the amount of fresh frozen plasma and worthy of clinical application.